Clinical Trial

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Name: A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer — clinical trial record (NCT07332533)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.

Trial Details

NCT Number	NCT07332533
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	HER2-positive Gastric Cancer
Enrollment	490 participants
Start Date	2025-12-30
Primary Completion	2032-06-30 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-12